

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 August 2000 (24.08.2000)

PCT

(10) International Publication Number
WO 00/48606 A1

(51) International Patent Classification⁷: A61K 31/661,
31/6615, 31/664

(21) International Application Number: PCT/US00/03996

(22) International Filing Date: 16 February 2000 (16.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/120,478 18 February 1999 (18.02.1999) US

(71) Applicant: OXIGENE, INC. [US/US]; Suite 602, One
Copley Place, Boston, MA 02116 (US).

(72) Inventors: PERO, Ronald, W.; Tornaplatzen 3, S-223 63
Lund (SE). SHERRIS, David; 37 Neillian Crescent, Ja-
maica Plain, MA 02130 (US).

(74) Agent: DUNHAM, Christopher, C.; Cooper & Dunham
LLP, 1185 Avenue of the Americas, New York, NY 10036
(US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK,

DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(48) Date of publication of this corrected version:
11 October 2001

(15) Information about Correction:
see PCT Gazette No. 41/2001 of 11 October 2001, Section
II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION

(57) Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularization, by administering a suffi-
cient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases,
so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to
the highly cytotoxic dephosphorylated form.

WO 00/48606 A1



DOCKET NO. P-208614.9(PCT)(US) Atty.DSH

SERIAL NO.: 10/070,484

APPLICANT: Pinney et al.

TITLE: INDOLE-CONTAINING AND COMBRETASTATIN RELATED ANTI-MITOTIC...

The Assistant Commissioner of Trademarks (with the Patent and Trademark Office) acknowledges, and has stamped hereon the date of, receipt of the items checked below which were mailed: May 3, 2002.

☒ SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
☒ FORM PTO-1449 (REFERENCES)

First Class Mail

3138450v1

COMPOSITIONS AND METHODS FOR USE IN
TARGETING VASCULAR DESTRUCTION

5

CROSS REFERENCE TO RELATED APPLICATION

10 This application claims the priority benefit of copending
U.S. provisional patent application Serial No. 60/120,478,
filed February 18, 1999.

BACKGROUND OF THE INVENTION

15

This invention relates to methods of and compositions for
effecting targeted vascular destruction in warm-blooded
animals, including humans, and to procedures for identifying
drugs capable of such use.

20

The importance of vasculature to the growth of tumors is
an unquestioned scientific reality. Because one blood vessel
nourishes thousands of tumor cells, targeting tumor vasculature
as a molecular approach to cancer chemotherapies is becoming
one of the highest scientific priorities. Two drug models are
25 emerging, i.e., one that prevents the formation of new blood
vessels in the tumor (antiangiogenesis) and one that targets
vascular destruction as a means of limiting tumor nourishment
and/or the impermeability of the luminal surface of vessel
endothelial cells to cancer drugs such as immunotherapies (New
30 England Journal of Medicine 339:473-474, 1998). The antiangi-
ogenic model is basically a cytostatic approach where angiogen-
ic factors generally produced by tumors such as vascular
endothelial growth factor (VEGF) and platelet derived endothe-
lial cell growth factor, are blocked by antiangiogenic com-
35 pounds such as the natural polypeptides angiostatin and
endostatin to prevent new blood vessel growth (The Cancer
Journal Scientific American 4(4):209-216, 1998; Cell 88:277-
285, 1997). On the other hand, the vascular destruction model
is a cytotoxic approach where tumor vessels are targeted for

cytotoxicity in order to enhance tumor cell cytotoxicity by hypoxia or direct acting chemotherapy.

One of the most potent classes of cancer therapeutic drugs is the antimitotic tubulin polymerization inhibitors (Biochem. Molecular Biology Int. 25(6):1153-1159, 1995; Br. Journal Cancer 71(4):705-711, 1995; Journal Med. Chem. 34(8):2579-2588, 1991; Biochemistry 28(17):6904-6991, 1989). They characteristically have IC_{50} in vitro cell cytotoxicities in the nM- μ M range, but often show poor specificity for killing tumor over normal tissues in vivo, examples of such drugs including combretastatins, taxol (and other taxanes), vinblastine (and other vinca alkaloids), colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, flavanoids, rhizoxins, curacins A, epothilones A and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo (2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans and 2,3-substituted indoles (Journal of Med. Chem. 41(16):3022-3032, 1998; Journal Med. Chem. 34(8):2579-2588, 1991; Anticancer Drugs 4(1):19-25, 1993; Pharm. Res. 8(6):776-781, 1991; Experimentia 45(2):209-211, 1989; Med. Res. Rev. 16:2067, 1996; Tetrahedron Lett. 34:1035, 1993; Mol. Pharmacol. 49:288, 1996; J. Med. Chem. 41:1688-1695, 1998; J. Med. Chem. 33:1721, 1990; J. Med. Chem. 34:2579, 1991; J. Md. Chem. 40:3049, 1997; J. Med. Chem. 40:3525, 1997; Bioorg. Med. Chem. Lett. 9:1081-1086, 1999; International (PCT) Application No. US 98/04380; U.S. Provisional Patent Application No. 60/154,639). Although tubulin binding agents in general can mediate effects on tumor blood flow, doses that are effective are often also toxic to other normal tissues and not particularly toxic to tumors (Br. J. Cancer 74(Suppl. 27):586-88, 1996).

Many tubulin binding agents such as the combretastatins and taxol analogs are water insoluble and require formulation before evaluation in the clinic. One approach which has been used successfully to overcome this clinical development problem is the formulation of biolabile water soluble prodrugs, such as the phosphate salt derivatives of combretastatin A4 and taxol,

that allow metabolic conversion back into the water insoluble form (Anticancer Drug Des. 13(3):183-191, 1998; U.S. patent No. 5,561,122; Bioorganic Med. Chem. Lett. 3:1766, 1993; Bioorganic Med. Chem. Lett. 3:1357, 1993). A prodrug is a precursor which will undergo metabolic activation in vivo to the active drug. Stated with further reference to the aforementioned phosphate salt derivatives, the concept here is that non-specific phosphatases such as alkaline phosphatases in mammals are capable of dephosphorylating phosphate prodrugs into the original biologically active forms. This prior art teaches how to administer a water insoluble drug to warm blooded animals for therapeutic purposes under conditions of more maximum absorption and bioavailability by formulation into a water soluble biolabile form (Krogsgaard-Larsen, P. and Bundegaard, H., eds., A textbook of Drug Design and Drug Development, Harvard Academic Publishers, p. 148, 1991).

When the combretastatin A4 phosphate prodrug was used in in vitro and in vivo cell and animal models, it displayed a remarkable specificity for vascular toxicity (Int. J. Radiat. Oncol. Biol. Phys. 42(4):895-903, 1998; Cancer Res. 57(10):1829-1834, 1997). It was not obvious from this to one skilled in the art that phosphate prodrugs in general, which serve as substrates for alkaline phosphatase, had anything to do whatsoever with vascular targeting. However, the reported data on the combretastatin A4 phosphate prodrug did disclose the principle of preferential vascular toxicity, even though there was no understanding or appreciation of the fact that the prodrug itself was responsible for vascular targeting. In other words, the prior art teaches that A4 and not A4 prodrug was responsible for vascular toxicity by assuming that there was no difference in vascular toxicity between the two forms. The nonobviousness noted above is exemplified by the fact that, although A4 phosphate prodrug and other taxol phosphate prodrugs were promoted as susceptible to phosphatase conversion to the cytotoxic tubulin binding forms, it was never recognized that this enzyme was elevated in microvessels thus targeting them to cytotoxicity.

SUMMARY OF THE INVENTION

An object of the invention is to provide compositions and methods useful in targeting the microvessel destruction model for the treatment, in warm-blooded animals including (but not limited to) humans, of cancer, Kaposi's sarcoma, and other, non-malignant vascular proliferative disorders such as macular degeneration, psoriasis and restenosis, and, in general, inflammatory diseases characterized by vascular proliferation.

Another object is to provide procedures for identifying drugs that are capable of use in producing such compositions and performing such methods.

To these and other ends, the present invention in a first aspect broadly contemplates the provision of a method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug other than combretastatin A4 disodium phosphate effective to achieve targeted vascular destruction at a locality of proliferating vasculature, wherein the prodrug is substantially noncytotoxic but is convertible to a substantially cytotoxic drug by action of an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation.


In a second aspect, the invention contemplates the provision of a method of treating a warm-blooded animal having a nonmalignant vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug effective to achieve targeted vascular destruction at a locality of proliferating vasculature, wherein the prodrug is substantially noncytotoxic but is convertible to a substantially cytotoxic drug by action of an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation.

In a further aspect, the invention contemplates the provision of compositions for treating a warm-blooded animal having a vascular proliferative disorder to achieve targeted vascular destruction at a locality of proliferating vasculature, comprising a prodrug, other than combretastatin A4,

pancratistatin and taxol phosphate prodrugs, which is substantially noncytotoxic but is convertible to a substantially cytotoxic drug by action of an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation.

5 In yet another aspect, the invention provides a procedure for identifying prodrugs suitable for use in the above methods and compositions, such procedure comprising the steps of culturing proliferating endothelial cells, and other cells, in the presence of a prodrug other than combretastatin A4 disodium
10 phosphate for a limited time period; comparing the respective cultures thereafter to determine whether the culture of proliferating endothelial cells exhibits a significantly greater cytotoxic effect than the culture of other cells; and, if so, culturing the aforesaid other cells in the presence of
15 the prodrug and an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation, enhanced cytotoxic effect with respect to the other cells in the presence of the enzyme as compared to the cytotoxic effect in the initial culture of the other cells indicating suitability
20 of the prodrug for such methods and compositions. Conveniently or preferably, the "other cells" may be nonmalignant fibroblasts, e.g., normal human fibroblasts.

In an important specific sense, to which however the invention is in its broadest aspects not limited, the prodrug
25 in the foregoing methods, compositions and procedures may be a phosphate within the class of compounds having the general formula



35 wherein

X is O, NH, or S;


Y is O, NH, S, O⁻, NH⁻ or S⁻;

Z is O or S;

each of R^2 and R^3 is an alkyl group, H, a mono- or divalent cationic salt, or an ammonium cationic salt, and R^2 and R^3 may be the same or different; and

R^1 is defined by the formula R^1-R^a representing a compound that contains at least one group (designated R^a) which is a group, containing X, that can form a phosphate or other salt that serves as a substrate for non-specific vascular endothelial phosphatases, and is thereby converted from a relatively non-cytotoxic phosphate form to a cytotoxic R^1-R^a form.

Currently preferred prodrugs for the practice of the invention are those having the following formulas:



More particularly, the compound with formula R^1-R^a may be a tubulin binder. In specific aspects it may be selected from the known tubulin binding agents already previously listed such as the combretastatins, taxanes, vinblastine (vinca alkaloids), colchicinoids, dolastatins, podophyllotoxins, steganacins, amphetiniles, flavanoids, rhizoxins, curacins A, epothilones A and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans and 2,3-substituted indoles. In a still more specific sense, this tubulin binder may be a compound selected from the group consisting of combretastatins (other than combretastatin A4), colchicine, and 2-methoxy estradiol.

Stated with reference to phosphate prodrugs, for an understanding of the invention it may be explained that vascular endothelial cells have high levels of phosphatase activity because of (i) stress injury response of microvessels due to blood circulation (J. Invest. Dermatol. 109(4):597-603, 1997) and (ii) the induction of phosphatase in vascular endothelial cells by IL-6 produced by inflammatory cells during wound

healing or by invasive tumor cells (FEBS Lett. 350(1):99-103, 1994; Ann. Surg. Oncol. 5(3):279-286, 1998). High levels of phosphatases (e.g. alkaline) are a part of the normal physiology of microvessels, because together with the blood clotting mechanism, calcium deposits generated from alkaline phosphatase activity aid in the wound healing process. The present invention embraces the discovery that phosphate or other appropriate prodrug constructs, which become substrates for phosphatases such as alkaline phosphatases, are useful in targeting microvascular toxicity. Examples of phosphatase enzymes suitable for this purpose require an ectoplasmic cellular location because of the poor absorption of phosphorylated molecules through the cytoplasmic membrane. Dephosphorylating enzymes known to have an ectoplasmic location are non-specific alkaline phosphatases, ATPase, ADPase, 5'-nucleotidase, and purine nucleoside phosphorylase. Another property necessary for targeting cytotoxic agents by dephosphorylation via phosphatases is that they could utilize a broad spectrum of phosphate prodrugs as substrates. In this regard, alkaline phosphatase is an attractive target for delivering selective toxicity to vascular endothelial cells.

Further features and advantages of the invention will be apparent from the detailed description hereinbelow set forth, together with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B and 1C illustrate the structures of various cytotoxic compounds and noncytotoxic prodrugs thereof as examples of molecular diversity capable of targeting microvascular cellular toxicity by formation of phosphate prodrugs;

FIGS. 2A and 2B are graphs showing the effect of exposure time on combretastatin A4 prodrug cytotoxicity;

FIGS. 3A and 3B are graphs showing the effect of alkaline phosphatase on cultured HMVEC and HDF;

FIGS. 4A and 4B are graphs showing the dose response effect of added alkaline phosphatase on the cytotoxicity of HMVEC and HDF to A4 prodrug; and

5 FIG. 5 is a series of graphs showing the effects of exposure time on the clonogenic toxicity induced by a variety of tubulin binding drugs.

DETAILED DESCRIPTION

10

This invention embraces the use of phosphate prodrugs comprising administering to warm-blooded animals having a tumor or non-malignant hypervascularization, a sufficient amount of a cytotoxic agent formulated into a prodrug form having substrate
15 specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form. Examples of preferred cytotoxic agents for vascular targeting are tubulin binding
20 agents, because they can be transformed from water insolubility to water solubility, tubulin binding agents to non-tubulin binding agents, and cytotoxicity to non-cytotoxicity by phosphate prodrug formulation (Anti-Cancer Drug Design 13: 183-191, 1998).

25

Examples of the molecular diversity for targeting microvessel cellular toxicity by formation of phosphate prodrugs are presented in FIGS. 1A-1C, and they were selected from the known tubulin binding agents already previously listed such as the combretastatins, taxanes, vinblastine (vinca alkaloids),
30 colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, flavanoids, rhizoxins, curacins A, epothilones A and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans and 2,3-substituted indoles. The
35 compounds listed in FIGS. 1A-1C satisfy the structural requirements of having either aromatic hydroxyl or amino groups


present capable of chemical reaction to produce a phosphate salt, and the further conversion of a cytotoxic agent into a non-cytotoxic phosphate prodrug construct. Other criteria necessary for targeting vascular toxicity are:

- 5 1. Tubulin binding agents or other cytotoxic agents (e.g. pancratistatin has not been reported to bind to tubulin polymers) must induce similar levels of toxicity to both human microvessel cells and other normal human cells such as fibroblasts when in the cytotoxic (tubulin binding) form, or, alternatively, the tubulin binding form must be
10 much less inherently cytotoxic to normal cells than to microvessel cells. If this were not the case and fibroblasts (i.e. normal cells) were much more sensitive than microvessels to the cytotoxic form, then when in the non-
15 cytotoxic prodrug form, even though fibroblasts had much less phosphatase to activate the cytotoxic form, much less would in turn be needed to induce cytotoxicity in fibroblasts. The net result would be that prodrugs could still be more toxic to microvessels instead of normal cells,
20 because of their enhanced alkaline phosphatase activity producing the cytotoxic form.
2. The tubulin binding or cytotoxic forms of potential phosphate prodrugs must not be cytotoxic in the prodrug form, which in turn needs to be converted into the
25 cytotoxic form within 1-3 hours, preferably within 1-2 hours. Tubulin binding agents clear from peripheral circulation within a few hours. So in order to be effective in targeting vascular destruction in vivo, the phosphate prodrug constructs must be converted to the
30 cytotoxic forms within 1-3 hours by phosphatase in the microvessels in order to elicit a preferential toxicity of the cells. Hence, the kinetics of binding to tubulin must be nearly complete within 1-3 hours.

35 Although high levels of alkaline phosphatase are useful for targeting vascular destruction of tubulin binding agents, this invention also embraces, in a broader sense, that any enzyme or protein specifically amplified in microvessels, and that is

capable of converting metabolically a nontoxic prodrug into a cytotoxic drug, would be equally useful in targeting vascular destruction.

5 Compositions in accordance with the invention having use in targeting vascular destruction are illustratively exemplified, without limitation, by compounds embraced within the class of compounds having the general formula



15 wherein R¹ is defined by the formula R¹-R^a representing a compound that contains at least one group (designated R^a) which is a phenolic hydroxyl group, or an aromatic amino group, or any other appropriate hydroxyl or amino group, that can form R²-R³ phosphate metal or amine salts or phosphate esters that serve
20 as substrates for non-specific vascular endothelial phosphatases, and are thereby converted from a relatively non-cytotoxic phosphate form to a cytotoxic hydroxyl or amino form.

Thus, in illustrative embodiments, R¹ is defined by the formula R¹-R^a representing a compound that contains at least one
25 phenolic hydroxyl group (designated R^a) that can form a sodium phosphate or other appropriate salt (e.g., R², R³ may be Li, Na, K, Ca, Cs, Mg, Mn, Zn, piperazine, nicotinamide and other examples as found in International (PCT) patent application No. 99/US/5368, the entire disclosure of which is incorporated
30 herein by this reference) that serves as a substrate for non-specific vascular endothelial phosphatases, and that is thereby converted from a relatively non-cytotoxic phosphate form to the cytotoxic phenolic hydroxyl form.

The invention particularly embraces discoveries made in
35 ascertaining the heretofore unknown explanation for the observed apparent selective targeting of proliferating endothelial cells by combretastatin A4 disodium phosphate, and in recognizing the applicability of those discoveries to drugs other than combretastatin A4 and to the treatment of nonmalignant

nant as well as malignant disorders involving vascular proliferation.

The pertinent studies respecting combretastatin A4 disodium phosphate will now be further described.

5 Chemicals. GMP manufactured combretastatin A4 disodium phosphate was purchased from OXiGENE, Inc. (Boston) and dissolved in physiological saline for addition to cell cultures. Alkaline phosphatase was purchased from Sigma (P-6774) as a buffered solution and was added to cell cultures directly.

10 Cell culture. Four commercially available human cell lines were grown in the indicated media below in 5% CO₂, 80% humidity and 37°C:

1. HL60 human leukemic cells, a pro-apoptotic cell line -- cultured in RPMI 1640 fortified with 10% fetal calf serum.
- 15 2. K562 human leukemic cells, an apoptotic-resistant cell line -- cultured in RPMI 1640 fortified with 10% fetal calf serum.
- 20 3. Human neonatal microvascular endothelial cells (HMVEC) -- cultured in medium 131 + microvascular growth supplement (MVGS) + attachment factor (AF) = 500 ml + 25 ml (AF is added 2-3 ml/T-25 flask; all reagents supplied by Cascade Biologics, Inc., Portland, Oregon).
- 25 4. Human neonatal dermal fibroblasts (HDF) -- cultured in medium 106 + low serum growth supplement (LSGS) = 500 ml + 10 ml (Cascade Biologics, Inc.).

30 The cells used in all experiments were first subcultured up to 2-3 days at an initial density of 2×10^5 cells/ml prior to use in the vitro assays. This resulted in an exponential growth stage and the cell viability was >95% by trypan blue exclusion.

35 Cell survival by clonogenic assay. This assay is based on a description reported by Schweitzer et al. (Expt. Haematol. 21: 573-578, 1993) with slight modifications. Briefly, HL60 and K562, HDF, HMVEC cells at concentrations of 4.2×10^3 /ml were cultured in 96-well flat-bottomed microculture plates in a

volume of 190 μ l per well plus different concentrations of combretastatin A4 disodium phosphate or other tubulin binding agents and their prodrugs or units of alkaline phosphatase added in a 10 μ l volume. After 5 days of incubation under the standard culture conditions stated above, colonies (>40 cells) were counted by an inverted light microscope or estimated by MTT assay. IC₅₀ values were obtained from the fitted curves of percentage of the control versus the drug concentrations.

Alkaline phosphatase metabolism of combretastatin A4 disodium phosphate to the highly cytotoxic combretastatin A4. There were three types of experiments designed to demonstrate the importance to convert A4 prodrug to A4 in order to target toxicity to vascular endothelial cells.

Experiment 1. HL60, K562, HDF, and HMVEC cells were either cultured in 96-well plates at the indicated concentrations (FIGS. 2A and 2B) for 5 days in the presence of A4 prodrug, or after 2 hours exposure the drug-containing media was removed, fresh media added, and the cells cultured for an additional 5 days. Clonogenic growth was recorded after 5 days incubation for all treatments.

Experiment 2. HMVEC and HDF were cultured in 96-well microtiter plates initially containing 800 cells/well. The cells were cultured for 1 hour in the presence of the indicated concentrations of A4 prodrug \pm 1 unit of alkaline phosphatase. The medium was removed, the cells washed, and fresh medium added, and the cells were incubated for an additional 5 days. Clonogenic growth was then established by the MTT assay.

Experiment 3. HMVEC were cultured in 96-well microtiter plates initially containing 800 cells/well. The cells were cultured for 1 hour in the presence of the indicated concentrations of A4-prodrug \pm the indicated units of alkaline phosphatase. The medium was removed, the cells were washed in medium, and the cultures were further incubated in fresh medium for an additional 5 days. Clonogenic growth was then established by the MTT assay.

Referring to the drawings, FIGS. 2A and 2B are graphs showing the effect of exposure time on A4 prodrug cytotoxicity.

HMVEC, HDF, HL60, and K562 cells were exposed for 2 hours (FIG. 2A) or 5 days (FIG. 2B) to combretastatin A4 disodium phosphate before clonogenic cytotoxicity was estimated at 5 days. Note that the IC_{50} values were similar for all the cells after 5 days exposure being 1.5 to 2.5 nM whereas only HMVEC showed IC_{50} cytotoxicity when exposure was limited to 2 hours.

FIGS. 3A and 3B are graphs showing the effect of alkaline phosphatase on cultured HMVEC and HDF. Dose response cytotoxicity was estimated after 1 hour exposure to various concentrations of combretastatin A4 disodium phosphate in the presence or absence of 1 unit alkaline phosphatase. Note the lack of cytotoxicity of HDF without added alkaline phosphatase, but the cytotoxicity of A4 prodrug was the same for HMVEC and HDF when alkaline phosphatase was added.

FIGS. 4A and 4B are graphs showing the dose response effect of added alkaline phosphatase on the cytotoxicity of HMVEC and HDF to A4 prodrug. HMVEC and HDF were cultured for 1 hour in the presence of the indicated concentrations of added combretastatin A4 disodium phosphate + the indicated units of added alkaline phosphatase. The data clearly showed added dependence of the alkaline phosphatase on the cytotoxicity especially at the higher A4 prodrug concentrations.

EXAMPLE 1

Example 1 discloses the importance of time of exposure to the preferential cytotoxicity of vascular endothelial cells to tubulin binding agents such as combretastatin A4 prodrug. If the clonogenic assay is set up to treat HMVEC, HDF, K562 and HL60 cells for 5 days in the presence of increasing concentrations of combretastatin A4 disodium phosphate (prodrug), all the cell lines had similar IC_{50} values of about 1.5 to 2.5 nM (FIG. 2B). These data teach that there is no inherent difference in the toxicity of the human cell lines regardless of their origin, if the exposure time is long enough. However, A4 prodrug, as well as other tubulin binding drugs, clear from peripheral circulation in vivo within a few hours, and under these conditions A4 prodrug showed a preferential toxicity to

proliferating endothelial cells in tumors, whereas other tubulin binding agents have not been shown to possess this property (Cancer Res. 57(10):1829-1834, 1997). Hence, we have limited the exposure of the various cell lines to A4 prodrug for 2-3 hours, removed the A4-containing medium and replaced it with fresh medium, and continued culturing for an additional 5 days. These conditions showed that HMVEC were quite sensitive to A4 prodrug-induced cytotoxicity compared to the HDF, K562 and HL60 cells (FIG. 2A). These data teach that (i) an in vitro cell model can be used to demonstrate selective induction of toxicity to vascular endothelial cells by tubulin binding agents such as A4 prodrug, (ii) this only occurs under in vitro conditions that mimic in vivo pharmacokinetic-regulated limitations of exposure, and (iii) either tubulin binding parameters regulating cytotoxicity or metabolic differences or both are responsible for the selective toxicity of A4 prodrug to vascular endothelial cells.

EXAMPLE 2

The combretastatins are a family of naturally occurring tubulin binding agents comprising an A-, B-, C- and D- series of structures (U.S. patents Nos. 4,940,726; 4,996,237; 5,409,953; and 5,569,786). Example 2 compares the 1C50 values of the clonogenic toxicity induced by a selection of these compounds in in vitro cultures of HDF, HMVEC and HL-60. The compounds were added to microcultures in DMSO (i.e. <0.5%) and toxicity was evaluated by MTT assay after 5-7 days in culture. The data in Table 1 show that the combretastatin analogs varied considerably in their overall clonogenic toxicity between the various analogs as well as between the different human cell types being evaluated. A4 had the most toxic mechanism of binding tubulin in all the cell types tested, and it showed no preference for clonogenic toxicity between the cell types. However, the cytotoxicity of the other combretastatins generally could be ranked according to the clonogenic toxicity of greatest to least toxic as:

HL-60 > HDF > HMVEC.

These data establish the prerequisite for tubulin binding drugs to have a property whereby toxicity to normal cells is not much greater than that to HMVEC, if phosphate prodrugs are to be used in vascular targeting of antimitotic toxicity.

5

TABLE 1

IC₅₀ clonogenic toxicity values in nM

	<u>Combretastatin</u>	<u>HDF</u>	<u>HMVEC</u>	<u>HL-60</u>
	A4	1-2	1-2	1-2
10	A3	8-10	>12	5
	A2	25-35	30-40	15
	A1	20	500	n.d.
	B1	200-300	200-300	500
	B2	1100	800-1000	125
15	K-228	40-90	90-120	90
	K-332	800-900	>1000	500

Combretastatins were kindly supplied by Professor G.R. Pettit of Arizona State University. HDF = human diploid fibroblasts; HMVEC = human microvessel endothelial cells; HL-60 = human myeloid leukemic cells

20

EXAMPLE 3

The effect of exposure time on the clonogenic toxicity induced by a variety of tubulin binding drugs is presented in FIG. 5. Taxol, taxotere, vincristine, and combretastatins A1 and A4 were added to microcultures of HMVEC and HDF for 1 and 6 hours, washed with saline and incubation continued in complete medium for 3 more days before estimating clonogenic toxicity by MTT assay. The data in this example show that the kinetics of binding of various tubulin binding drugs influences their cytotoxicity under conditions that are similar to *in vivo* exposure (i.e. 1 hour). For example, taxol, taxotere and Combretastatin A1 did not induce maximum toxicity to HMVEC after 1 hour exposure but required 6 hours, and in addition, the degree of kinetic-regulated cytotoxic responses were also different in HDF compared to HMVEC.

30

35

Hence, in order to target microvessel toxicity in humans the tubulin binding cytotoxic mechanism needs to be completed

within a 1-3 hour period after treatment in a manner that permits the toxicity to HMVEC to be comparable to HDF or other normal cells. When this is the case then phosphate prodrugs are able to target microvessel toxicity because they have elevated alkaline phosphatase compared to normal cells to transform the prodrug into its cytotoxic form.

EXAMPLE 4

Both stress injury and the presence of invasive tumor cells can induce microvessels to produce up to 50-fold increased levels of alkaline phosphatase (J. Invest. Dermatol. 109(4):597-603, 1997; FEBS Lett. 350(1):99-103, 1994). Alkaline phosphatases present in cell membranes and circulation can hydrolyze organic phosphate-containing compounds separating or freeing the phosphate salt portion (e.g. calcium phosphate) from the organic molecule portion. The physiological need of microvessels to repair damage to themselves by elevating alkaline phosphatases is a part of normal wound healing process leading to an increased deposition of calcium deposits in the injured area. A consequence of this metabolic specificity may be that cytotoxic tubulin binding agents modified into a phosphate salt (e.g. A4 prodrug) may also be a substrate for alkaline phosphatase. This process then could in turn lead to an increased cytotoxic sensitivity of microvessels to tubulin binding drugs, that do not bind tubulin in a phosphorylated form and are not cytotoxic to the dephosphorylated form which does bind tubulin and is cytotoxic. This example shows that indeed this is the case. HDF and HMVEC exposed to in vitro culture for 2 hours to increasing concentrations of A4 prodrug in the presence or absence of 1 unit of added alkaline phosphatase, demonstrate a high degree of selective cytotoxicity to HMVEC without added alkaline phosphatase, but HDF become identically cytotoxic as HMVEC to A4 prodrug in the presence of added alkaline phosphatase (FIGS. 3A and 3B). It was concluded that targeting vascular destruction was directly dependent on the presence of high levels of alkaline phosphatase in HMVEC, and the lack of it in other normal and tumor cells such as HDF.

Hence, this example teaches a method for targeting preferential destruction of microvessels, whereby cytotoxic agents such as tubulin binding compounds, which when converted into a prodrug form by for example forming a phenolic hydroxy phosphate salt that cannot induce cytotoxicity, can be selectively metabolized by alkaline phosphatase, that is present in high amounts only in vascular endothelial cells, back into a cytotoxic form.

EXAMPLE 5

Example 5 further establishes and verifies the disclosure presented in Example 4. Here, the experimental design was designed to demonstrate the dose dependence of alkaline phosphatase on regulating cytotoxicity of A4 prodrug. The data clearly show how the amount of alkaline phosphatase determines the clonogenic cytotoxicity of combretastatin A4 disodium phosphate to both HMVEC and HDF (FIGS. 4A and 4B). The results teach that more alkaline phosphatase must be added before HDF can be killed by A4 prodrug, whereas HMVEC directly express clonogenic toxicity to A4 prodrug without or after addition of low levels of alkaline phosphatase, but at high added levels of alkaline phosphatase the toxicities become equal for both cell lines.

It is therefore demonstrated that *in vivo* targeting of tumor vascular destruction is directly dependent on alkaline phosphatase, and that this knowledge would be useful in designing agents and methods for the treatment of cancer and other, non-malignant, vascular proliferating disorders.

EXAMPLE 6

The compounds presented in Table 2 represent examples of how toxicity can be targeted to microvessel cells by converting the cytotoxic forms into phosphate prodrugs, which are in turn not cytotoxic until converted back into the cytotoxic form by cellular phosphatases such as alkaline phosphatase, which has ≥ 50 -fold higher concentration in proliferating microvessel endothelial cells than other normal cells. In general, tubulin binding drugs cannot bind tubulin in the phosphate salt form,

and so they represent a cytotoxic mechanism preferred as a cytotoxic mechanism for vascular targeting. All of the compounds were evaluated for toxicity after a one-hour exposure in microculture and assayed for cytotoxicity by MTT assay after an additional 5 days' incubation in culture. Under these conditions, the kinetics of tubulin binding were sufficiently rapid to cause toxicity in both normal proliferating HDF and HMVEC. The data reported in Table 2 establish that (i) phosphate prodrugs in general spare normal HDF from toxicity while not affecting the toxicity to HMVEC as shown by higher IC_{50} values for the prodrugs in HDF but not HMVEC, (ii) if the cytotoxic agent is more toxic to HDF than to HMVEC, then even though the prodrug spares toxicity in HDF it cannot make up for the difference in inherent toxicities between HDF and HMVEC, (iii) not all metal or amine salts of phosphate prodrugs are equally effective since combretastatin A1 piperazine phosphate was only marginally effective at protecting HDF from cytotoxicity, and (iv) because pancratistatin is not known to bind tubulin, compounds having other cytotoxic mechanisms can also be targeted by the phosphatase mechanism. In summation, these data show that cytotoxic agents can target microvessel cellular destruction by phosphate prodrug construction, if there is protection for normal cells having little alkaline phosphatase to metabolize enough of the phosphate prodrug to its cytotoxic form within one hour of exposure (i.e., mimics *in vivo* conditions).

TABLE 2

Evidence for targeting microvessel cellular toxicity by converting cytotoxic compounds into non-cytotoxic phosphate prodrugs (Note: "FIG. 1 No." in the left-hand column refers to the structure identification number in FIGS. 1A, 1B and 1C of the drawings. Compounds I to VIII were supplied by Professor G.R. Pettit of Arizona State University and compounds X to XVI by Dr. Kevin G. Pinney of Baylor University in Waco, TX)

FIG. 1 No.	Cytotoxic form	Non-cytotoxic form (prodrug)	IC ₅₀ values	
			HMVEC	HDF
1	Combretastatin A4		75-150nM	50nM
2		Combretastatin A4 Na ₂ PO ₄	75-150nM	>500nM
3	Combretastatin A1		10-15μM	>0.5-1μM
4		Combretastatin A1 Na ₂ PO ₄	10-15μM	5-10μM
5	Combretastatin A1		10-15μM	>0.5-1μM
6		Combretastatin A1 Piperazine PO ₄	10-15μM	1-2μM
7	Combretastatin A1		10-15μM	>0.5-1μM
8		Combretastatin A1 Nicotinamide PO ₄	10-15μM	>10μM
10		Amino Combretastatin A4 Phosphoroamidate	8-10μM	15-20μM
11	Dihydronaphthalene		0.5-1μM	0.5-1μM
12		Dihydronaphthalene Phosphoroamidate	5-7μM	>50μM
13	Pancratistatin		20-25μM	20μM
14		Pancratistatin Na ₂ PO ₄	20-25μM	60-80μM
15	Benzo (a) thiophene		5-10μM	5-10μM
16		Benzo (a) thiophene Na ₂ PO ₄	8-10μM	30-40μM

EXAMPLE 7

To simulate pathogenic ocular angiogenesis, ocular neovascularization was induced by administration of lipid hydroperoxide (LHP) by intra-corneal injection at a dosage of 30 μ g to rabbit eyes. Seven to 14 days later, ocular vessels formed in the injected eyes due to LHP insult. The subjects were divided into two groups; those of one group were given combretastatin A4 disodium phosphate by intravenous administration at a dosage of 40mg/kg once a day for five days, while a vehicle without combretastatin A4 disodium phosphate was administered to the other group by i.v. administration as a dosage of water for the same time period. The eyes of both groups were examined seven days later. A reduction of vessels of 40% or more was observed in the group treated with combretastatin A4 disodium phosphate, but not in the other group.

It is to be understood that the invention is not limited to the features and embodiments hereinabove specifically set forth, but may be carried out in other ways without departure from its spirit.

CLAIMS

WHAT IS CLAIMED IS:

5 1. A method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug other than combretastatin A4 disodium phosphate effective to achieve targeted vascular destruction at a locality of proliferating vasculature, wherein
10 the prodrug is substantially noncytotoxic but is convertible to a substantially cytotoxic drug by action of an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation.

15 2. A method according to claim 1, wherein the prodrug is a phosphate within the class of compounds having the general formula



25 wherein

X is O, NH, or S;

Y is O, NH, S, O⁻, NH⁻ or S⁻;

Z is O or S;

30 each of R² and R³ is an alkyl group, H, a mono- or divalent cationic salt, or an ammonium cationic salt, and R² and R³ may be the same or different; and

35 R¹ is defined by the formula R¹-R^a representing a compound that contains at least one group (designated R^a) which is a group, containing X, that can form a phosphate or other salt that serves as a substrate for non-specific vascular endothelial phosphatases, and is thereby converted from a relatively non-cytotoxic phosphate form to a cytotoxic R¹-R^a form.

3. A method according to claim 2, wherein the compound with formula R^1-R^a is a tubulin binder.

4. A method according to claim 3, wherein the tubulin binder may be a compound selected from the group consisting of combretastatins, taxanes, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, flavanoids, rhizoxins, curacins A, epothilones A and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles and 2-methoxy estradiol.

5. A method according to claim 1, wherein the animal has microvessel cells at the locality of vascular proliferation, wherein the animal also has other cells which are nonmalignant, and wherein the substantially cytotoxic drug is not substantially more toxic to said nonmalignant other cells than to said microvessel cells.

6. A method according to claim 5, wherein the prodrug is converted to the substantially cytotoxic drug by the action of the endothelial enzyme within a period of not more than about three hours.

7. A method according to claim 1, wherein the prodrug is converted to the substantially cytotoxic drug by the action of the endothelial enzyme within a period of not more than about three hours.

8. A method of treating a warm-blooded animal having a nonmalignant vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug effective to achieve targeted vascular destruction at a locality of proliferating vasculature, wherein the prodrug is substantially noncytotoxic but is convertible to a substantially cytotoxic

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/03996

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/661, 31/6615, 31/664

US CL : 514/137, 143

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/137, 143

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DARK et al. Combretastatin A-4 an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature. Cancer Research. 15 May 1997, Vol. 57, No. 10, pages 1829-1834, see entire document.	1-26



Further documents are listed in the continuation of Box C.



See patent family annex.

* *A* *E* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *Z*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	---	--------------------------	--

Date of the actual completion of the international search

22 JUNE 2000

Date of mailing of the international search report

06 JUL 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHYLLIS SPIVACK

Telephone No. (703) 308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL PATENT

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/03996

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/661, 31/6615, 31/664

US CL : 514/137, 143

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/137, 143

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DARK et al. Combretastatin A-4 an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature. Cancer Research. 15 May 1997, Vol. 57, No. 10, pages 1829-1834, see entire document.	1-26.

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 JUNE 2000

Date of mailing of the international search report

06 JUL 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

PHYLLIS SPIVACK

Telephone No. (703) 308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL PATENT

drug by action of an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation.

9. A method according to claim 8, wherein the prodrug is a phosphate within the class of compounds having the general formula



wherein

X is O, NH, or S;

Y is O, NH, S, O⁻, NH⁻ or S⁻;

Z is O or S;

each of R² and R³ is an alkyl group, H, a mono- or divalent cationic salt, or an ammonium cationic salt, and R² and R³ may be the same or different; and

R¹ is defined by the formula R¹-R^a representing a compound that contains at least one group (designated R^a) which is a group, containing X, that can form a phosphate or other salt that serves as a substrate for non-specific vascular endothelial phosphatases, and is thereby converted from a relatively non-cytotoxic phosphate form to a cytotoxic R¹-R^a form.

10. A method according to claim 9, wherein the compound with formula R¹-R^a is a tubulin binder.

30

11. A method according to claim 10, wherein the tubulin binder may be a compound selected from the group consisting of combretastatins, taxanes, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphetiniles, flavanoids, rhizoxins, curacins A, epothilones A and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substi-

tuted benzo(b)furans, 2,3-substituted indoles and 2-methoxy estradiol.


12. A method according to claim 8, wherein the animal has microvessel cells at the locality of vascular proliferation, wherein the animal also has other cells, and wherein the substantially cytotoxic drug is not substantially more toxic to said other cells than to said microvessel cells.

13. A method according to claim 12, wherein the prodrug is converted to the substantially cytotoxic drug by the action of the endothelial enzyme within a period of not more than about three hours.

14. A method according to claim 8, wherein the prodrug is converted to the substantially cytotoxic drug by the action of the endothelial enzyme within a period of not more than about three hours.

15. A composition for treating a warm-blooded animal having a vascular proliferative disorder to achieve targeted vascular destruction at a locality of proliferating vasculature, comprising a prodrug, other than combretastatin A4, pancratistatin and taxol phosphate prodrugs, which is substantially noncytotoxic but is convertible to a substantially cytotoxic drug by action of an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation.

16. A composition as defined in claim 15, wherein the prodrug is a phosphate within the class of compounds having the general formula



wherein

X is O, NH, or S;

Y is O, NH, S, O⁻, NH⁻ or S⁻;

Z is O or S;

each of R² and R³ is an alkyl group, H, a mono- or divalent
5 cationic salt, or an ammonium cationic salt, and R² and R³ may
be the same or different; and

R¹ is defined by the formula R¹-R^a representing a compound
that contains at least one group (designated R^a) which is a
group, containing X, that can form a phosphate or other salt
10 that serves as a substrate for non-specific vascular endotheli-
al phosphatases, and is thereby converted from a relatively
non-cytotoxic phosphate form to a cytotoxic R¹-R^a form.

17. A composition as defined in claim 16, wherein the
15 compound with formula R¹-R^a is a tubulin binder.

18. A composition as defined in claim 17, wherein the
tubulin binder may be a compound selected from the group
consisting of combretastatins, taxanes, vinca alkaloids,
20 colchicinoids, dolastatins, podophyllotoxins, steganacins,
amphethiniles, flavanoids, rhizoxins, curacins A, epothilones A
and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones,
stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroin-
dolo(2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substi-
25 tuted benzo(b)furans, 2,3-substituted indoles and 2-methoxy
estradiol.

19. A composition as defined in claim 15, wherein the
animal has microvessel cells at the locality of vascular
30 proliferation, wherein the animal also has other cells which
are nonmalignant, and wherein the substantially cytotoxic drug
is not substantially more toxic to said nonmalignant other
cells than to said microvessel cells.


35 20. A method according to claim 19, wherein the prodrug
is converted to the substantially cytotoxic drug by the action

of the endothelial enzyme within a period of not more than about three hours.

21. A method according to claim 15, wherein the prodrug is converted to the substantially cytotoxic drug by the action of the endothelial enzyme within a period of not more than about three hours.

22. Procedure for identifying prodrugs suitable for use in the above methods and compositions, such procedure comprising the steps of culturing proliferating endothelial cells, and other cells which are nonmalignant, in the presence of a prodrug other than combretastatin A4 disodium phosphate for a limited time period; comparing the respective cultures thereafter to determine whether the culture of proliferating endothelial cells exhibits a significantly greater cytotoxic effect than the culture of other cells; and, if so, culturing the aforesaid other cells in the presence of the prodrug and an endothelial enzyme selectively induced at enhanced levels at sites of vascular proliferation, enhanced cytotoxic effect with respect to the other cells in the presence of the enzyme as compared to the cytotoxic effect in the initial culture of the other cells indicating suitability of the prodrug for such methods and compositions.

23. Procedure according to claim 22, wherein the prodrug is a phosphate within the class of compounds having the general formula



wherein

X is O, NH, or S;

Y is O, NH, S, O⁻, NH⁻ or S⁻;

Z is O or S;

each of R^2 and R^3 is an alkyl group, H, a mono- or divalent cationic salt, or an ammonium cationic salt, and R^2 and R^3 may be the same or different; and

R^1 is defined by the formula R^1-R^a representing a compound that contains at least one group (designated R^a) which is a group, containing X, that can form a phosphate or other salt that serves as a substrate for non-specific vascular endothelial phosphatases, and is thereby converted from a relatively non-cytotoxic phosphate form to a cytotoxic R^1-R^a form.

10

24. Procedure according to claim 23, wherein the compound with formula R^1-R^a is a tubulin binder.

15

25. Procedure according to claim 24, wherein the tubulin binder may be a compound selected from the group consisting of combretastatins, taxanes, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, flavanoids, rhizoxins, curacins A, epothilones A and B, welwistatins, phenstatins, 2-strylquinazolin-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a)isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles and 2-methoxy estradiol.

20

25

26. Procedure according to claim 22, wherein said nonmalignant other cells are fibroblasts.

1/6

Microvessel Cellular Toxicity by Formation of Phosphate Prodrugs





FIG. 1A

2/6


*Cytotoxic Form**Non-Cytotoxic Form*

9




Amino Combretastatin A4
1-(3 amino -4 - methoxy phenyl) 2-
(3,4,5 - tri methoxy phenyl) - ethene

10




PM-VI-19C
Amino Combretastatin A4
Phosphoro amidate prodrug

11




Amino dihydronaphthalene analog

12




Amino dihydronaphthalene phosphoro amidate

13




Pancratistatin

14




Pancratistatin sodium phosphate prodrug

15



VPM-V-150
3-(3', 4', 5' -trimethoxybenzoyl) -2
(4'-methoxy - 5' hydroxy phenyl) -6-
methoxybenzo (b) thiophene

16




VPM-W-152
benzo(b)thiophene sodium phosphate prodrug

FIG. 1B

3/6

Cytotoxic Form


17



3-(3', 4', 5'-trimethoxy benzoyl) -2-(4'-methoxy - 5' hydroxy phenyl) -6-methoxy indole


Non-Cytotoxic Form

18




Indole sodium phosphate prodrug

19




Colchicine

20




Colchicine sodium phosphate prodrug

21



2-Methoxyestradiol


22




2-Methoxyestradiol sodium phosphate prodrug

FIG. 1C


4 cell lines treated with Combretastatin A4 Prodrug for 2 hours, then cultured for 5 days and assayed by the MTT-method

**FIG. 2A**


4 cell lines cultured for 5 days in the presence of Combretastatin A4 Prodrug and assayed by the MTT-method

**FIG. 2B**



No alkaline phosphatase added

**FIG. 3A**

1 unit/well alkaline phosphatase added

**FIG. 3B**

5/6

**FIG. 4A****FIG. 4B**

6/6




FIG. 5

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference BAY515/00414	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/25408	International filing date (day/month/year) 15 SEPTEMBER 2000	Priority date (day/month/year) 17 SEPTEMBER 1999
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant BAYLOR UNIVERSITY		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>5</u> sheets.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>0</u> sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement VI <input checked="" type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 16 APRIL 2001	Date of completion of this report 27 MARCH 2002
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box POT Washington, D.C. 20231	Authorized officer CHANA AULAKH
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235

I. Basis of the report**1. With regard to the elements of the international application:***☒ the international application as originally filed☒ the description:pages 1-25, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the claims:pages 26-40, as originally filedpages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the drawings:pages 1-12, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the sequence listing part of the description:pages NONE, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☒ The amendments have resulted in the cancellation of:**☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).****

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

US00/25408

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	<u>1-47</u>	YES
	Claims	<u>NONE</u>	NO
Inventive Step (IS)	Claims	<u>1-47</u>	YES
	Claims	<u>NONE</u>	NO
Industrial Applicability (IA)	Claims	<u>1-47</u>	YES
	Claims	<u>NONE</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-47 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the instant compounds of claims 1-40 and a method for inhibiting tubulin polymerization using these compounds.

NEW CITATIONS

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

/US00/25408

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

Application No. Patent No.	Publication Date (day/month/year)	Filing Date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 00/48606	24 AUGUST 2000	16 FEBRUARY 2000	NONE

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)
_____	_____	_____

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/25408

Supplemental B x

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): A61K 31/404; A 61P 43/00; C07D 209/12; C07F 9/24, 9/572 and US Cl.: 514 419, 148, 137; 548/491; 558/199